Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.MPM BioImpact fully exited its position in Crinetics Pharmaceuticals during the third quarter, a move disclosed in the fund’s November 14 SEC filing. The transaction reduced assets by approximately $12.3 million.What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, MPM BioImpact sold its entire holding of 428,975 shares in Crinetics Pharmaceuticals (CRNX +2.9 ...